Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis

ConclusionThese findings suggest that anakinra appears to be effective in treating pediatric patients with non –malignancy‐associated secondary HLH/MAS, especially when it is given early in the disease course and when administered to patients who have an underlying rheumatic disease.

Source: Arthritis and Rheumatology - December 25, 2019 Category: Rheumatology Authors: Esraa M. Eloseily, Peter Weiser, Courtney B. Crayne, Hilary Haines, Melissa L. Mannion, Matthew L. Stoll, Timothy Beukelman, T. Prescott Atkinson, Randy Q. Cron Tags: Original Article Source Type: research